Meeting
2023 ASCO Annual Meeting
Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: A prospective, single-arm, multicenter study.
Authors
Zhibo Zhang
The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
Zhibo Zhang , Maolin Yan , Yufeng Chen , Xukun Wu , Lanfang Yang , Zhengyu Yin , Hao Lu , Yongyi Zeng , Hui Zhang , Jingyao Huang , Jiafei Chen , Liang Wang , Zhongwu Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
ChiCTR2100050410
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4072)
DOI
10.1200/JCO.2023.41.16_suppl.4072
Abstract #
4072
Poster Bd #
393
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Lenvatinib (LEN) combined with tislelizumab (TIS) plus transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II clinical trial.
First Author: Xiang Nong
Poster
2023 ASCO Annual Meeting
Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.
First Author: Jinpeng Li
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of envafolimab plus lenvatinib combined with TACE in unresectable hepatocellular carcinoma: An open-label, single-arm, phase 2 study—The CISLD-12 study.
First Author: Tingbo Liang
Poster
2024 ASCO Annual Meeting
PD-1 inhibitor (sintilimab) and lenvatinib plus TACE-HAIC as conversion therapy for initially unresectable HCC: A single-arm, phase 2 clinical trial (PLATIC).
First Author: Yunfei Yuan